Your browser doesn't support javascript.
loading
Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes.
Mima, Akira; Yasuzawa, Toshinori; Nakamura, Tomomi; Ueshima, Shigeru.
Afiliación
  • Mima A; Department of Nephrology, Osaka Medical College, Osaka, Japan. amima@osaka-med.ac.jp.
  • Yasuzawa T; Department of Health and Nutrition, Faculty of Health Science, Kio University, Nara, Japan.
  • Nakamura T; Department of Food Science and Nutrition, Faculty of Agriculture, Kindai University, Nara, Japan.
  • Ueshima S; Department of Food Science and Nutrition, Faculty of Agriculture, Kindai University, Nara, Japan.
Sci Rep ; 10(1): 5775, 2020 04 01.
Article en En | MEDLINE | ID: mdl-32238837
Diabetes-induced podocyte apoptosis is considered to play a critical role in the pathogenesis of diabetic kidney disease (DKD). We proposed that hyperglycaemia can induce podocyte apoptosis by inhibiting the action of podocyte survival factors, thus inactivating the cellular effects of insulin signalling. In this study, we aimed to determine the effects of linagliptin on high glucose-induced podocyte apoptosis. Linagliptin reduced the increase in DNA fragmentation as well as the increase in TUNEL-positive cells in podocytes induced by high-glucose condition. Furthermore, linagliptin improved insulin-induced phosphorylation of insulin receptor substrate 1 (IRS1) and Akt, which was inhibited in high-glucose conditions. Adenoviral vector-mediated IRS1 overexpression in podocytes partially normalised DNA fragmentation in high-glucose conditions, while downregulation of IRS1 expression using small interfering RNA increased DNA fragmentation even in low-glucose conditions. Because reactive oxygen species inhibit glomerular insulin signalling in diabetes and Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway is one of the most important intrinsic antioxidative systems, we evaluated whether linagliptin increased Nrf2 in podocytes. High-glucose condition and linagliptin addition increased Nrf2 levels compared to low-glucose conditions. In summary, linagliptin offers protection against DKD by enhancing IRS1/Akt insulin signalling in podocytes and partially via the Keap1/Nrf2 pathway. Our findings suggest that linagliptin may induce protective effects in patients with DKD, and increasing IRS1 levels could be a potential therapeutic target in DKD.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Transducción de Señal / Podocitos / Linagliptina / Glucosa / Hipoglucemiantes Límite: Animals Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Transducción de Señal / Podocitos / Linagliptina / Glucosa / Hipoglucemiantes Límite: Animals Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido